Kevin Maclay Speaks to Bloomberg on Purdue Pharma Settlement

Purdue Pharma is poised to wrap up all liability for its role in the opioid crisis in a matter of weeks after its $8.3 billion settlement with the Justice Department cleared the way to resolve outstanding bankruptcy claims.

. . .

A “positive sign,” the agency’s action “shows that the federal government is willing to allow most of the funds that it would have been able to assert a claim to flow into the abatement,” said Kevin Maclay, a lawyer with Caplin & Drysdale who represents more than 1,300 local government entities in the bankruptcy.

For the full article, please visit Bloomberg Law’s website (subscription required).